VedaBio

VedaBio is a provider of a molecular detection and editing platform using CRISPR Cascade technology. The platform offers near-instant molecular detection of multiplexed analytes without the need for target amplification, and can also be used for diagnostics, research, and therapeutic development. VedaBio leverages CRISPR-based technology to enable rapid, sensitive, and multiplexed molecular detection, transforming how diagnostics and research are conducted in genomics and molecular biology. Founded in 2021 and headquartered in San Diego, United States, VedaBio has raised approximately 40.1 million at the Series A stage with 26 employees and investors including OMX Ventures, Kleinmuntz Associates, Y Combinator, and Tao Capital Partners.